Derazantinib, an oral fibroblast growth factor receptor inhibitor, in phase-2 clinical development, shows anti-angiogenic activity in pre-clinical models. (October 2020) - Mcsheehy, P.; Boult, J.; Robinson, S.; Bachmann, F.; El Shemerly, M.; Kellenberger, L.; Lane, H.